Sanguine Diagnostics And Therapeutics, Inc.
Omaha, NE · Medtech · Private
Immunostaining kit and machine learning algorithm to classify colorectal polyp subtypes using MUC, MUC5AC, and CA markers for surveillance stratification
- Grants
- $6.7M
- 12 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20162017201820192020
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Ultrasensitive SERS Nano-Sensors for Pancreatic Cancer Diagnosis and Prognosis | $300,000 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Ultrasensitive SERS Nano-Sensors for Pancreatic Cancer Diagnosis and Prognosis | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase II · MUC4/16 assay for the early diagnosis and management of benign and malignant pancreatic diseases | $199,020 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Seromic Mucin Signature for the Early Diagnosis of Pancreatic Cancer | $196,647 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · MUC4/16 assay for the early diagnosis and management of benign and malignant pancreatic diseases | $657,713 | |
| Federal grant | Department of Health and Human Services · Phase II · MUC4/16 assay for the early diagnosis and management of benign and malignant pancreatic diseases | $1,315,426 | |
| Federal grant | Department of Health and Human Services · Phase II · Seromic Mucin Signature for the Early Diagnosis of Pancreatic Cancer | $1,300,714 | |
| Federal grant | Department of Health and Human Services · Phase II · Seromic Mucin Signature for the Early Diagnosis of Pancreatic Cancer | $650,357 | |
| Federal grant | Department of Health and Human Services · Phase II · MUC4/16 assay for the early diagnosis and management of benign and malignant pancreatic diseases | $657,713 | |
| Federal grant | Department of Health and Human Services · Phase I · Combinatorial Biomarkers for Malignant Polyps and Colon Cancer Detection | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Combinatorial Biomarkers for Malignant Polyps and Colon Cancer Detection | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Seromic Mucin Signature for the Early Diagnosis of Pancreatic Cancer | $650,357 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1910 | CLAIRWAYS LLC | — | — |
| 1911 | Nine Continents Medical Inc | — | — |
| 1912 | Neumora Therapeutics | — | $474M |
| 1913 | Sanguine Diagnostics And Therapeutics, Inc. | — | — |
| 1914 | GUANINE, INC. | — | — |
| 1915 | Advanced Biosensors Inc. | — | — |
| 1916 | Scilex Pharmaceuticals Inc. | — | $7.5M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.